nivolumab,ipilimumab
bms
['hcrn,gu16,260', 'hcrn,gu,16,260', 'nivolumab', 'nivo', 'renal,(-adrenal)']
determinants of resistance to #nivolumab monotherapy investigated through genomic and transcriptomic analysis of #renalcellcarcinoma tumors from the hcrn gu16-260 study. presented by . #asco23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology